TAK-861 (Lead Oral OX2R Agonist)
Investor Call on Phase 2b NT1 Data Presented at SLEEP 2024

from the beginning

TAK-861 (Lead Oral OX2R Agonist)

Important Notice

• Orexin Franchise Overview

TAK-861 has the potential to establish a new standard of care for patients withNT1-Setting the foundation for Takeda leadership in the orexin field

TAK-861 has the potential to address patient needs across the multiplesymptoms of NT1

Narcolepsy Type 1 symptoms are a result of loss of orexin neurons

Optimized dosing regimen is critical to deliver transformative efficacy whileminimizing on/off target Adverse Events

• Efficacy and Safety Results from the Ph2b Trial of TAK-861 in NT1 Patients

Study Design

Endpoints

Over the 8-week study period no participants discontinued due to adverse events

TAK-861 demonstrated statistically significant and clinically meaningful increased sleep latency on the MWT vs placebo

Most participants achieved ESS scores comparable to healthy individuals (10) with TAK-861

TAK-861 significantly reduced cataplexy events compared to placebo

TAK-861 was generally safe and well tolerated in participants with NT1 over 8 weeks

The majority insomnia were mild or moderate and resolved within 5 days

TAK-861 addresses aspects of disease burden important to people with NT1

Conclusions TAK-861 NT1 phase 2

Takeda is advancing the field of orexin therapeutics with a multi-asset franchise offering tailored treatments to unlock the full potential of orexin

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

Appendix

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@